ClinicalTrials.gg
TerminatedNCT01806740DCE-MRIUpdated Aug 8, 2019Results posted

DCE-MRI Using Dotarem® in Evaluation of Therapeutic Response to Sorafenib in Patients With Advanced Stage HCC

A Phase 4 interventional study of Gadoterate meglumine in Hepatocellular Carcinoma, sponsored by Guerbet. Terminated at 1 site in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2019-08-08.

Sponsored by Guerbet · Phase 4, Interventional, and Diagnostic

Why this study was terminated
The planned number of enrolled patients was not reached.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
37
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 298 studies in Carcinoma, Hepatocellular with a site in Korea, Republic of — 50 open to participants now, 74 under way, 8 of them phase 3. Carcinoma, Hepatocellular · Korea, Republic of.

Enrollment
196th of 255
37 · median 87
Started
2013
with 21 others
Phase 4
8 of 298
1 open now
Registered
75th of 298
by date

Among the 298 studies in Carcinoma, Hepatocellular with a site in Korea, Republic of, this one is the 196th largest by enrollment of the 255 interventional ones that give a count, is one of 22 that started in 2013, is one of 8 in phase 4, and was the 75th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

50 of the 298 studies in Carcinoma, Hepatocellular with a site in Korea, Republic of are open now. Recruiting first, the newest first:

45 more — sign in →

All 50 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 298 studies in Carcinoma, Hepatocellular with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The main objective is to evaluate the value of dynamic contrast-enhanced Magnetic Resonance Imaging (DCE-MRI) in prediction of response of patients with hepatocellular carcinoma (HCC) to treatment with Sorafenib assessed by mRECIST.

Read the detailed description

One of the secondary objectives was to evaluate the correlation between DCE-MRI perfusion parameters at baseline and:

  • Overall Survival (OS)
  • Progression-Free Survival (PFS)
  • Time to Progression (TTP)

Three DCE-MRI examinations were done during the study:

  • at the enrolment and initiation of the sorafenib treatment
  • one week after initiation of the sorafenib treatment
  • two weeks after initiation of the sorafenib treatment

DCE-MRI perfusion parameters were assessed by a centralized radiologist at baseline (corresponding to the day of enrolment and initiation of Sorafenib treatment), week 1 and week 2.

According to mRECIST criteria, HCC lesions were evaluated on computed tomography images by two on-site radiologists at the time of enrolment and 8 weeks later (2 months). OS, PFS and TTP were calculated from survival and tumor progression data recorded one year after initiation of the sorafenib treatment.

03

Conditions studied

  • Hepatocellular Carcinoma

Keywords

  • DCE-MRI
  • Sorafenib response
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  1. Male and female adult patients (age ≥ 20 years old)
  2. Patients diagnosed with unresectable HCC [ class A and major vascular invasion, extrahapatic , or progression after transarterial chemoembolization more than 2 times]
  3. Presence of target lesion within liver [lesion which can be classified as a (can be measured ≥ 1 cm in at least one dimension), lesion suitable for repeated measure, lesion showing intraluminal arterial enhancement on contrast-enhanced CT or MRI]
  4. Patients planned to be treated with sorafenib
  5. Patient with liver CT performed or planned to be performed within 4 weeks before initiation of sorafenib treatment
  6. Patient with a of 12 weeks or more
  7. No previous treatment with sorafenib
  8. Female patients who are surgically sterilized, or (minimum 12 months of amenorrhea) or who have a documented negative urine hCG test at screening
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 4
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    Gadoterate meglumine

    there is one single arm of patients (no comparative arm)

    Drug: Gadoterate meglumine

Interventions

  • Gadoterate meglumine was administered at a dose of 0.1 mmol/kg (0.2 mL/kg) using a power injector, in an intravenous bolus at a rate of 3 mL/sec.

    Also known as: gadoteric acid, Dotarem

06

What researchers measure

Primary outcomes

  1. Correlation Coefficient Between DCE-MRI Perfusion Parameters and the Response of Target Lesions to Sorafenib

    To evaluate the correlation between DCE-MRI perfusion parameters (Ktrans, AUC, ve, kep, T1, Wash-in, Washout) at baseline, week 1 and week 2, and the response of target lesions to sorafenib. * Ktrans: volume transfer constant between blood plasma and extravascular extracellular space * AUC : area under the curve of tissue gadolinium concentration-time * ve: fractional volume of extravascular extracellular space * kep: rate constant between extravascular extracellular space and blood plasma (=Ktrans/ve) * T1: longitudinal relaxation time * Wash-in: slope of the early enhancement curve * Washout: slope of the late enhancement curve The response of target lesions was assessed by mRECIST at 2 months after initiation of treatment (sorafenib). The correlation analyses were done using Pearson or Spearman correlation coefficient.

    Time frame: 3 months

Secondary outcomes

  1. Correlation Coefficient Between DCE-MRI Perfusion Parameters at Baseline and Overall Survival

    To evaluate the correlation between DCE-MRI perfusion parameters (Ktrans, AUC, ve, kep, T1, wash-in, washout) at baseline and overall survival. The overall survival was calculated from the patient's survival status recorded one year after initiation of the sorafenib treatment. The correlation analyses were done using Pearson or Spearman correlation coefficient.

    Time frame: 1 year

  2. Correlation Coefficient Between DCE-MRI Perfusion Parameters at Baseline and Progression Free Survival

    To evaluate the correlation between DCE-MRI perfusion parameters (Ktrans, AUC, ve, kep, T1, wash-in, washout) at baseline and progression free survival. The progression free survival was calculated from the patient's survival status and tumor progression status recorded one year after initiation of the sorafenib treatment. The correlation analyses were done using Pearson or Spearman correlation coefficient.

    Time frame: 1 year

  3. Correlation Coefficient Between DCE-MRI Perfusion Parameters at Baseline and Time to Progression

    To evaluate the correlation between DCE-MRI perfusion parameters (Ktrans, AUC, ve, kep, T1, wash-in, washout) at baseline and time to progression. The time to progression was calculated from the patient's survival status and tumor progression status recorded one year after initiation of the sorafenib treatment. The correlation analyses were done using Pearson or Spearman correlation coefficient.

    Time frame: 1 year

07

Results

Posted Aug 8, 2019
Limitations and caveats
The small number of patients included and analyzed was a major limitation to interpret the efficacy results, inducing high variability in DCE-MRI perfusion parameters, OS, PFS and TTP values.

Participant flow

Despite several extensions of the recruitment period, the planned number of enrolled patients was still not reached after 2 years and the study was prematurely discontinued. A total of 37 patients were enrolled in four study sites.

Participant flow — Overall Study
MilestoneGadoterate Meglumine
Started37
Completed31
Not completed6
Withdrew: Withdrawal by subject4
Withdrew: Physician decision1
Withdrew: Patient's refusal of treatment1

Outcome measures

PrimaryCorrelation Coefficient Between DCE-MRI Perfusion Parameters and the Response of Target Lesions to Sorafenib

To evaluate the correlation between DCE-MRI perfusion parameters (Ktrans, AUC, ve, kep, T1, Wash-in, Washout) at baseline, week 1 and week 2, and the response of target lesions to sorafenib. * Ktrans: volume transfer constant between blood plasma and extravascular extracellular space * AUC : area under the curve of tissue gadolinium concentration-time * ve: fractional volume of extravascular extracellular space * kep: rate constant between extravascular extracellular space and blood plasma (=Ktrans/ve) * T1: longitudinal relaxation time * Wash-in: slope of the early enhancement curve * Washout: slope of the late enhancement curve The response of target lesions was assessed by mRECIST at 2 months after initiation of treatment (sorafenib). The correlation analyses were done using Pearson or Spearman correlation coefficient.

Time frame:
3 months
Reported as:
Number · correlation coefficient
Correlation Coefficient Between DCE-MRI Perfusion Parameters and the Response of Target Lesions to Sorafenib
correlation coefficientBaselineWeek 1Week 2
Ktrans (mean)-0.29-0.38-0.38
AUC (mean)-0.53-0.60-0.62
ve (mean)-0.19-0.33-0.34
kep (mean)-0.07-0.24-0.17
T1 (mean)0.050.300.18
Wash-in (mean)-0.42-0.48-0.52
Washout (mean)-0.31-0.48-0.36
SecondaryCorrelation Coefficient Between DCE-MRI Perfusion Parameters at Baseline and Overall Survival

To evaluate the correlation between DCE-MRI perfusion parameters (Ktrans, AUC, ve, kep, T1, wash-in, washout) at baseline and overall survival. The overall survival was calculated from the patient's survival status recorded one year after initiation of the sorafenib treatment. The correlation analyses were done using Pearson or Spearman correlation coefficient.

Time frame:
1 year
Reported as:
Number · correlation coefficient
Correlation Coefficient Between DCE-MRI Perfusion Parameters at Baseline and Overall Survival
correlation coefficientBaseline
Ktrans (mean)0.09
AUC (mean)-0.08
ve (mean)0.35
kep (mean)-0.05
T1 (mean)-0.14
Wash-in (mean)-0.02
Washout (mean)-0.04
SecondaryCorrelation Coefficient Between DCE-MRI Perfusion Parameters at Baseline and Progression Free Survival

To evaluate the correlation between DCE-MRI perfusion parameters (Ktrans, AUC, ve, kep, T1, wash-in, washout) at baseline and progression free survival. The progression free survival was calculated from the patient's survival status and tumor progression status recorded one year after initiation of the sorafenib treatment. The correlation analyses were done using Pearson or Spearman correlation coefficient.

Time frame:
1 year
Reported as:
Number · correlation coefficient
Correlation Coefficient Between DCE-MRI Perfusion Parameters at Baseline and Progression Free Survival
correlation coefficientBaseline
Ktrans (mean)-0.24
AUC (mean)-0.45
ve (mean)0.17
kep (mean)-0.23
T1 (mean)-0.15
Wash-in (mean)-0.31
Washout (mean)-0.29
SecondaryCorrelation Coefficient Between DCE-MRI Perfusion Parameters at Baseline and Time to Progression

To evaluate the correlation between DCE-MRI perfusion parameters (Ktrans, AUC, ve, kep, T1, wash-in, washout) at baseline and time to progression. The time to progression was calculated from the patient's survival status and tumor progression status recorded one year after initiation of the sorafenib treatment. The correlation analyses were done using Pearson or Spearman correlation coefficient.

Time frame:
1 year
Reported as:
Number · correlation coefficient
Correlation Coefficient Between DCE-MRI Perfusion Parameters at Baseline and Time to Progression
correlation coefficientBaseline
Ktrans (mean)-0.72
AUC (mean)-0.64
ve (mean)-0.68
kep (mean)-0.17
T1 (mean)0.24
Wash-in (mean)-0.70
Washout (mean)-0.42

Adverse events

Collected over 3 months (from the informed consent signature to 2 months after initiation of the sorafenib treatment). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Gadoterate Meglumine1/31 (3.2%)7/31 (22.6%)29/31 (93.5%)
Most frequent serious events
Most frequent serious events
EventGadoterate Meglumine
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/31
Abdominal pain upperGastrointestinal disorders1/31
Tumor necrosisNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/31
Gastric varices haemorrhageGastrointestinal disorders1/31
Oesophageal varices haemorrhageGastrointestinal disorders1/31
Upper respiratory tract infectionInfections and infestations1/31
Hepatic encephalopathyNervous system disorders1/31
Cholecystitis acuteHepatobiliary disorders1/31
Respiratory failureRespiratory, thoracic and mediastinal disorders1/31
Most frequent other events
Showing 10 of 45
Most frequent other events
EventGadoterate Meglumine
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders15/31
DiarrhoeaGastrointestinal disorders10/31
NauseaGastrointestinal disorders6/31
Abdominal painGastrointestinal disorders5/31
RashSkin and subcutaneous tissue disorders4/31
Abdominal pain upperGastrointestinal disorders3/31
AlopeciaSkin and subcutaneous tissue disorders3/31
Blood pressure increasedInvestigations3/31
HeadacheNervous system disorders3/31
Decreased appetiteMetabolism and nutrition disorders3/31

Baseline characteristics

Age, Continuous
Age, Continuous(years)Gadoterate Meglumine
Mean60.06 ± 10.78
Sex: Female, Male
Sex: Female, Male(Participants)Gadoterate Meglumine
Female4
Male27
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Gadoterate Meglumine
American Indian or Alaska Native0
Asian31
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Weight
Weight(kg)Gadoterate Meglumine
Mean60.03 ± 9.17
08

Study locations

1 site
  • Guerbet Korea
    Seoul, Gangnam Gu 135-920, Korea, Republic of
09

References and documents

Individual participant data

Plan to share: Undecided — It will be decided after study completion.

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2013 to primary completion in Oct 2015, 29 months.

Results were first posted in Aug 2019, 3 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2012
First posted
Mar 7, 2013
StartActual
May 9, 2013
Primary completionActual
Oct 12, 2015
CompletionActual
Oct 12, 2015
Results first posted
Aug 8, 2019
Last update
Aug 8, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01806740
Lead sponsor
Guerbet
Responsible party
Sponsor
First posted
Mar 7, 2013
Start date
May 9, 2013
Primary completion
Oct 12, 2015
Completion
Oct 12, 2015
Results posted
Aug 8, 2019
Last update
Aug 8, 2019

Study contacts

Jeong Min Lee, Ph.D
principal investigator · Seoul National University Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gadoterate meglumine

Start the discussion